insights_auto
Why is TRVN down 99,24%?
Dive Deeperchevron_right
TRVN:OTCMKTS
Trevena Inc
0,00050 $
arrow_downward
-99,24%(-0,066) 1D
16 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TRVN...
Open
0,00 $
High
0,00 $
Low
0,00 $
Mkt. cap
407,21
Avg. vol.
210,00
Volume
4,13 мың
52-wk high
1,50 $
52-wk low
0,00 $
Beta
1,07
Shares outstanding
864,00 м.
No. of employees
23
Open
0,00 $
High
0,00 $
Low
0,00 $
Mkt. cap
407,21
Avg. vol.
210,00
Volume
4,13 мың
52-wk high
1,50 $
52-wk low
0,00 $
Beta
1,07
Shares outstanding
864,00 м.
No. of employees
23
News stories
From web sources and news partners
Simply Wall Street
·
26 минут бұрын
Caught Out By Peloton Interactive’s Fall? Here’s What Bears Saw
Seeking Alpha
·
34 минут бұрын
Earnings Scoreboard: 83% of S&P 500 early reporters beat EPS estimates as Y/Y profit growth hits 23 firms
MarketBeat
·
22 минут бұрын
Cintas Corporation (NASDAQ:CTAS) Stock Has Consensus Target Price of $218.50 According to Analysts
Yahoo Finance
·
4 сағат бұрын
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees23
Founded2007
HeadquartersАтланта, Джорджия, Америка Құрама Штаттары
Sector-
Websitetrevena.com